Rocket Pharmaceuticals (RCKT) Competitors $2.92 +0.06 (+2.10%) Closing price 08/11/2025 04:00 PM EasternExtended Trading$2.94 +0.02 (+0.68%) As of 08:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RCKT vs. VERA, ABCL, CDTX, NTLA, HROW, CVAC, CALT, PHVS, PAHC, and AVDLShould you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Vera Therapeutics (VERA), AbCellera Biologics (ABCL), Cidara Therapeutics (CDTX), Intellia Therapeutics (NTLA), Harrow (HROW), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Pharvaris (PHVS), Phibro Animal Health (PAHC), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Rocket Pharmaceuticals vs. Its Competitors Vera Therapeutics AbCellera Biologics Cidara Therapeutics Intellia Therapeutics Harrow CureVac Calliditas Therapeutics AB (publ) Pharvaris Phibro Animal Health Avadel Pharmaceuticals Rocket Pharmaceuticals (NASDAQ:RCKT) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has higher valuation & earnings, RCKT or VERA? Vera Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$258.75M-$2.51-1.16Vera TherapeuticsN/AN/A-$152.15M-$3.58-5.63 Do institutionals and insiders believe in RCKT or VERA? 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 24.8% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is RCKT or VERA more profitable? Vera Therapeutics' return on equity of -46.70% beat Rocket Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -63.19% -54.69% Vera Therapeutics N/A -46.70%-39.46% Do analysts prefer RCKT or VERA? Rocket Pharmaceuticals presently has a consensus price target of $16.33, indicating a potential upside of 459.36%. Vera Therapeutics has a consensus price target of $63.00, indicating a potential upside of 212.35%. Given Rocket Pharmaceuticals' higher probable upside, research analysts plainly believe Rocket Pharmaceuticals is more favorable than Vera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 1 Sell rating(s) 9 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.35Vera Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has more risk & volatility, RCKT or VERA? Rocket Pharmaceuticals has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Does the media favor RCKT or VERA? In the previous week, Rocket Pharmaceuticals had 11 more articles in the media than Vera Therapeutics. MarketBeat recorded 44 mentions for Rocket Pharmaceuticals and 33 mentions for Vera Therapeutics. Rocket Pharmaceuticals' average media sentiment score of 0.02 beat Vera Therapeutics' score of -0.32 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 33 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Vera Therapeutics 4 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryVera Therapeutics beats Rocket Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCKT vs. The Competition Export to ExcelMetricRocket PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$308.61M$3.00B$5.48B$9.72BDividend YieldN/A2.28%4.59%4.13%P/E Ratio-1.1617.0529.7724.63Price / SalesN/A347.15455.03102.60Price / CashN/A40.7324.8127.99Price / Book0.578.898.595.76Net Income-$258.75M-$54.75M$3.26B$264.95M7 Day Performance-3.95%-2.71%-0.33%-0.01%1 Month Performance-1.35%4.43%2.12%1.27%1 Year Performance-84.59%19.64%44.65%26.11% Rocket Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCKTRocket Pharmaceuticals4.8395 of 5 stars$2.92+2.1%$16.33+459.4%-84.7%$308.61MN/A-1.16240Trending NewsEarnings ReportAnalyst ForecastGap UpVERAVera Therapeutics2.8911 of 5 stars$20.45-2.4%$65.00+217.8%-43.9%$1.30BN/A-6.8240Earnings ReportABCLAbCellera Biologics3.2262 of 5 stars$4.34+2.4%$8.75+101.6%+67.9%$1.27B$28.83M0.00500Earnings ReportCDTXCidara Therapeutics3.3934 of 5 stars$62.46-0.7%$57.29-8.3%+425.0%$1.26B$1.27M-2.1290News CoverageEarnings ReportNTLAIntellia Therapeutics4.5598 of 5 stars$12.12+5.5%$33.37+175.3%-50.0%$1.26B$45.57M-2.32600Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHROWHarrow2.3447 of 5 stars$33.42+7.0%$63.83+91.0%-6.1%$1.23B$212.86M-59.68180CVACCureVac4.3793 of 5 stars$5.46+0.9%$6.83+25.2%+65.5%$1.22B$523.70M5.93880Upcoming EarningsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PHVSPharvaris1.9048 of 5 stars$21.24+6.2%$36.20+70.4%+29.6%$1.11BN/A-7.0630Upcoming EarningsHigh Trading VolumePAHCPhibro Animal Health4.1584 of 5 stars$27.14+3.9%$24.40-10.1%+62.1%$1.10B$1.02B34.801,940Positive NewsAVDLAvadel Pharmaceuticals2.6274 of 5 stars$11.26+1.6%$18.33+62.8%-17.5%$1.07B$169.12M0.0070News CoveragePositive NewsEarnings ReportAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies VERA Competitors ABCL Competitors CDTX Competitors NTLA Competitors HROW Competitors CVAC Competitors CALT Competitors PHVS Competitors PAHC Competitors AVDL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RCKT) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access